KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$5.9 million.

  • Bionano Genomics' Cash from Operations rose 5566.91% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.7 million, marking a year-over-year increase of 7971.3%. This contributed to the annual value of -$68.9 million for FY2024, which is 4494.21% up from last year.
  • As of Q3 2025, Bionano Genomics' Cash from Operations stood at -$5.9 million, which was up 5566.91% from -$3.5 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Cash from Operations high stood at -$2.8 million for Q1 2025, and its period low was -$36.7 million during Q2 2023.
  • Its 5-year average for Cash from Operations is -$21.2 million, with a median of -$25.6 million in 2021.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 13370.25% in 2022, then skyrocketed by 9004.66% in 2025.
  • Bionano Genomics' Cash from Operations (Quarter) stood at -$25.6 million in 2021, then plummeted by 34.72% to -$34.5 million in 2022, then increased by 13.73% to -$29.8 million in 2023, then soared by 78.16% to -$6.5 million in 2024, then increased by 9.29% to -$5.9 million in 2025.
  • Its last three reported values are -$5.9 million in Q3 2025, -$3.5 million for Q2 2025, and -$2.8 million during Q1 2025.